Non-Hormonal Contraceptives Market Report 2026

The non-hormonal contraceptives market size has grown strongly in recent years. It will grow from $25.47 billion in 2025 to $27.32 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to limited availability of non-hormonal contraceptive methods, reliance on surgical sterilization, growing awareness of reproductive health, increasing female healthcare initiatives, adoption of barrier devices in clinics.

The non-hormonal contraceptives market size is expected to see strong growth in the next few years. It will grow to $35.8 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to development of advanced non-hormonal devices, rising demand for reversible and minimally invasive sterilization, expansion of family planning programs, increasing awareness of safety and compliance standards, integration of smart contraceptive monitoring systems. Major trends in the forecast period include rising preference for non-hormonal contraceptive methods, growing adoption of barrier and mechanical devices, increasing awareness about reversible sterilization options, expansion of minimally invasive contraceptive devices, focus on safety, compliance, and patient-centric design.

The rising prevalence of sexually transmitted diseases is expected to drive growth in the non-hormonal contraceptives market in the coming years. Sexually transmitted diseases (STDs) are infections primarily spread through sexual contact and caused by bacteria, viruses, or parasites. The increase in STDs is largely linked to decreased condom usage, which raises the risk of infection during unprotected sexual activity. Non-hormonal contraceptives, including male and female condoms, help prevent the spread of STDs by acting as a physical barrier that blocks the exchange of bodily fluids. For example, in April 2025, the Minnesota Department of Health (MDH), a U.S.-based state health agency, reported that the proportion of HIV cases among males aged 35 to 39 rose from 10% in 2023 to 17% in 2024. This indicates that the growing prevalence of STDs is fueling growth in the non-hormonal contraceptives market.

Key companies in the non-hormonal contraceptives market are focusing on developing innovative solutions, such as preloaded intrauterine device (IUD) delivery systems, to simplify insertion, enhance user convenience, and improve clinical efficiency. A preloaded IUD delivery system is a ready-to-use device that integrates the IUD and inserter into a single unit, streamlining insertion, reducing setup time, and minimizing contamination or handling errors. For instance, in September 2024, CooperSurgical Inc., a U.S.-based medical device and fertility company, introduced the Paragard Single-Handed Inserter to improve insertion efficiency and patient comfort during non-hormonal IUD placement. The device provides over 99% effective, long-term contraception for up to 10 years, offering immediate, reversible, hormone-free birth control with minimal maintenance.

In November 2023, Daré Bioscience Inc., a U.S.-based biopharmaceutical company, partnered with Premier Research International LLC to extend their collaboration and support the clinical development of Daré’s women’s health programs. This partnership aims to accelerate clinical timelines, improve study execution through expanded operational support, enhance trial management efficiency, and advance novel women’s health candidates toward regulatory milestones. Premier Research International LLC is a U.S.-based clinical research organization providing full-service development support for biotechnology and medical technology companies.

Major companies operating in the non-hormonal contraceptives market are Church & Dwight Co., Okamoto Industries, CooperSurgical Inc., PSI India Pvt Ltd., Karex Berhad, Fuji Latex Co. Ltd., PREGNA INTERNATIONAL LTD., Cupid Limited, Global Protection Corp., SMB Corporation of India, HLL Lifecare Limited, Contraline Inc.

North America was the largest region in the non-hormonal contraceptives market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-hormonal contraceptives market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the non-hormonal contraceptives market by increasing the cost of imported medical devices and surgical instruments, particularly affecting barrier devices, tubal rings, and implantable plugs. Asia-Pacific regions such as India and China are most impacted due to high import duties on manufacturing equipment and components. While tariffs have raised production costs and slowed supply chain efficiency, they also promote domestic manufacturing, encourage innovation in device design, and create opportunities for local suppliers to expand.

The non-hormonal contraceptives market research report is one of a series of new reports that provides non-hormonal contraceptives market statistics, including non-hormonal contraceptives industry global market size, regional shares, competitors with a non-hormonal contraceptives market share, detailed non-hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the non-hormonal contraceptives industry. This non-hormonal contraceptives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-hormonal contraceptives are methods of preventing pregnancy that do not rely on hormones to alter a woman’s reproductive system. They work through physical barriers, chemical agents, or natural tracking methods, allowing individuals to prevent pregnancy without affecting the body’s hormonal balance.

The main types of non-hormonal contraceptives include devices, sterilization, and others. Devices are physical tools, instruments, or equipment designed to perform specific functions, often used in medical, industrial, or consumer applications. Their mechanisms of action may involve functioning as antagonists, agonists, inhibitors, or modulators. These products can be administered through various routes, such as intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal, and others. They are intended for both disease treatment and symptom management. Target indications for these contraceptives include bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis, and more.

The non-hormonal contraceptives market consists of sales of male condoms, copper intrauterine devices (IUDs), diaphragms, cervical caps, and spermicides. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.